Skip to main content
Top
Published in: Calcified Tissue International 6/2009

01-06-2009

May an Altered Hypothalamo–Pituitary–Adrenal Axis Contribute to Cortical Bone Damage in Primary Hyperparathyroidism?

Authors: Laura Gianotti, Francesco Tassone, Anna Pia, Silvia Bovio, Giuseppe Reimondo, Gianluca Visconti, Massimo Terzolo, Giorgio Borretta

Published in: Calcified Tissue International | Issue 6/2009

Login to get access

Abstract

Cortisol secretion has been reported to be increased in primary hyperparathyroidism (PHPT). Our aim was to evaluate circulating and urinary cortisol levels and the relationships with biochemical and bone parameters in patients with PHPT at the time of diagnosis. We studied 180 consecutive patients with PHPT (mean age ± SD 60.0 ± 13.2 years; F/M 140/40, BMI 25.8 ± 4.8 kg/m2) and 56 subjects with incidentally discovered adrenal adenoma who served as controls (age 56.2 ± 12.8 years, F/M 40/16, BMI 25.7 ± 3.9 kg/m2). Serum morning and midnight cortisol and urinary free cortisol were measured in both groups. In PHPT patients bone mineral density was measured at the lumbar spine, femur, and forearm. Serum morning cortisol and urinary cortisol were similar in PHPT patients and controls, whereas midnight cortisol was higher in PHPT patients (5.3 ± 4.7 vs. 2.9 ± 0.9 μg/dL, P = 0.001). In this group, midnight cortisol correlated positively with age (r = 0.27, P = 0.008) and negatively with forearm (r = −0.36, P = 0.003) and total-femur T score (r = −0.30, P = 0.02). Multivariate regression analysis, including age, calcium, parathyroid hormone (PTH), and midnight cortisol as independent variables and forearm T score as dependent variable, indicated that age (β = –0.29, P < 0.0001), PTH (β = –0.33, P < 0.0001), and midnight cortisol (β = –0.14, P < 0.04) were independently associated with forearm T score. Our findings show increased midnight cortisol levels in patients with PHPT, indicating a subtle alteration of the hypothalamo–pituitary–adrenal axis dynamics that is unrelated to the degree of disease activity; further data are needed to demonstrate the supplementary effect of this subtle alteration to bone damage in this condition.
Literature
1.
go back to reference Khan A, Bilezikian J (2000) Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 163:184–187PubMed Khan A, Bilezikian J (2000) Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 163:184–187PubMed
2.
go back to reference Silverberg SJ, Shane E, Dempster DW, Bilezikian JP (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561–567PubMedCrossRef Silverberg SJ, Shane E, Dempster DW, Bilezikian JP (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561–567PubMedCrossRef
3.
go back to reference Gianotti L, Tassone F, Cesario F, Pia A, Razzore P, Magro G, Piovesan A, Borretta G (2006) A slight decrease in renal function further impairs bone mineral density in primary hyperparathyroidism. J Clin Endocrinol Metab 91:3011–3016PubMedCrossRef Gianotti L, Tassone F, Cesario F, Pia A, Razzore P, Magro G, Piovesan A, Borretta G (2006) A slight decrease in renal function further impairs bone mineral density in primary hyperparathyroidism. J Clin Endocrinol Metab 91:3011–3016PubMedCrossRef
4.
go back to reference Rosenberg J, Pines M, Hurwitz S (1987) Response of adrenal cells to parathyroid stimulation. J Endocrinol 112:431–437PubMedCrossRef Rosenberg J, Pines M, Hurwitz S (1987) Response of adrenal cells to parathyroid stimulation. J Endocrinol 112:431–437PubMedCrossRef
5.
go back to reference Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG (2001) PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab 280:E209–E213PubMed Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG (2001) PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab 280:E209–E213PubMed
6.
go back to reference Yoshida T, Mio M, Tasaka K (1993) Ca++-induced cortisol secretion from permeabilized bovine adrenocortical cells: the roles of calmodulin, protein kinase C and cyclic AMP. Pharmacology 46:181–192PubMedCrossRef Yoshida T, Mio M, Tasaka K (1993) Ca++-induced cortisol secretion from permeabilized bovine adrenocortical cells: the roles of calmodulin, protein kinase C and cyclic AMP. Pharmacology 46:181–192PubMedCrossRef
7.
go back to reference Fuleihan GE-H, Brown EM, Gleason R, Scott J, Adler GK (1996) Calcium modulation of adrenocorticotropin levels in women—a clinical research study. J Clin Endocrinol Metab 81:932–936PubMedCrossRef Fuleihan GE-H, Brown EM, Gleason R, Scott J, Adler GK (1996) Calcium modulation of adrenocorticotropin levels in women—a clinical research study. J Clin Endocrinol Metab 81:932–936PubMedCrossRef
8.
go back to reference Brismar K, Werner S, Bucht E, Wetterber L (1987) Melatonin, cortisol, prolactin, and calcitonin secretion in primary hyperparathyroidism before and after surgery. J Pineal Res 4:277–285PubMedCrossRef Brismar K, Werner S, Bucht E, Wetterber L (1987) Melatonin, cortisol, prolactin, and calcitonin secretion in primary hyperparathyroidism before and after surgery. J Pineal Res 4:277–285PubMedCrossRef
9.
go back to reference Richards AM, Espiner EA, Nicholls MG, Ikram H, Hamilton EJ, Maslowski AH (1988) Hormone, calcium and blood pressure relationships in primary hyperparathyroidism. J Hypertens 6:747–752PubMedCrossRef Richards AM, Espiner EA, Nicholls MG, Ikram H, Hamilton EJ, Maslowski AH (1988) Hormone, calcium and blood pressure relationships in primary hyperparathyroidism. J Hypertens 6:747–752PubMedCrossRef
10.
go back to reference Linder J, Brimar K, Granberg PO, Wetterberg L, Werner S (1988) Characteristic changes in psychiatric symptoms, cortisol and melatonin but not prolactin in primary hyperparathyroidism. Acta Psychiatr Scand 78:32–40PubMedCrossRef Linder J, Brimar K, Granberg PO, Wetterberg L, Werner S (1988) Characteristic changes in psychiatric symptoms, cortisol and melatonin but not prolactin in primary hyperparathyroidism. Acta Psychiatr Scand 78:32–40PubMedCrossRef
11.
go back to reference Patschan D, Loddenkemper K, Buttgereit F (2001) Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29:498–505PubMedCrossRef Patschan D, Loddenkemper K, Buttgereit F (2001) Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29:498–505PubMedCrossRef
12.
go back to reference Lafage-Proust MH, Boudignon B, Thomas T (2003) Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine 70:109–118PubMedCrossRef Lafage-Proust MH, Boudignon B, Thomas T (2003) Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine 70:109–118PubMedCrossRef
13.
go back to reference Mancini T, Doga M, Mazziotti G, Giustina A (2004) Cushing’s syndrome and bone. Pituitary 7:249–252PubMedCrossRef Mancini T, Doga M, Mazziotti G, Giustina A (2004) Cushing’s syndrome and bone. Pituitary 7:249–252PubMedCrossRef
14.
go back to reference Rubin MR, Biliezikian JP (2002) The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87:4033–4041PubMedCrossRef Rubin MR, Biliezikian JP (2002) The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87:4033–4041PubMedCrossRef
15.
go back to reference National Institutes of Health Conference (1991) Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 114:593–597 National Institutes of Health Conference (1991) Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 114:593–597
16.
go back to reference Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A (2002) Adrenal incidentaloma: a new cause of the metabolic sindrome? J Clin Endocrinol Metab 87:998–1003PubMedCrossRef Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A (2002) Adrenal incidentaloma: a new cause of the metabolic sindrome? J Clin Endocrinol Metab 87:998–1003PubMedCrossRef
17.
go back to reference Findling JW, Raff H (2006) Cushing’s syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91:3746–3746PubMedCrossRef Findling JW, Raff H (2006) Cushing’s syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91:3746–3746PubMedCrossRef
18.
go back to reference Terzolo M, Bovio S, Reimondo G, Pia A, Osella G, Borretta G, Angeli A (2005) Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 34:423–439PubMedCrossRef Terzolo M, Bovio S, Reimondo G, Pia A, Osella G, Borretta G, Angeli A (2005) Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 34:423–439PubMedCrossRef
19.
go back to reference Newell-Price J, Trainer P, Besser M, Grossman A (1988) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19:647–672CrossRef Newell-Price J, Trainer P, Besser M, Grossman A (1988) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19:647–672CrossRef
20.
go back to reference Ferrari E, Cravello L, Muzzoni B, Casarotti D, Paltro M, Solerte SB, Fioravanti M, Cuzzoni G, Pontiggia B, Magri F (2001) Age-related changes of the hypothalamic–pituitary–adrenal axis: pathophysiological correlates. Eur J Endocrinol 144:319–329PubMedCrossRef Ferrari E, Cravello L, Muzzoni B, Casarotti D, Paltro M, Solerte SB, Fioravanti M, Cuzzoni G, Pontiggia B, Magri F (2001) Age-related changes of the hypothalamic–pituitary–adrenal axis: pathophysiological correlates. Eur J Endocrinol 144:319–329PubMedCrossRef
21.
go back to reference Chrousos GP, Kino T (2007) Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10:213–219PubMedCrossRef Chrousos GP, Kino T (2007) Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10:213–219PubMedCrossRef
22.
go back to reference Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, Santini SA, Guglielmi G, Carnevale V, Scillitani A (2007) Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med 147:541–548PubMed Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, Santini SA, Guglielmi G, Carnevale V, Scillitani A (2007) Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med 147:541–548PubMed
23.
go back to reference Torlontano M, Chiodini I, Pileri M, Guglielmi G, Cammina M, Modoni S, Carnevale V, Trischitta V, Scillitani A (1999) Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. J Clin Endocrinol Metab 84:2381–2385PubMedCrossRef Torlontano M, Chiodini I, Pileri M, Guglielmi G, Cammina M, Modoni S, Carnevale V, Trischitta V, Scillitani A (1999) Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. J Clin Endocrinol Metab 84:2381–2385PubMedCrossRef
24.
go back to reference Chiodini I, Torlontano M, Carnevale V, Trischitta V, Scillitani A (2008) Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest 31:267–276PubMed Chiodini I, Torlontano M, Carnevale V, Trischitta V, Scillitani A (2008) Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest 31:267–276PubMed
25.
go back to reference Cooper MS (2008) 11Beta-hydroxysteroid dehydrogenase: a regulator of glucocorticoid response in osteoporosis. J Endocrinol Invest 31:16–21PubMed Cooper MS (2008) 11Beta-hydroxysteroid dehydrogenase: a regulator of glucocorticoid response in osteoporosis. J Endocrinol Invest 31:16–21PubMed
Metadata
Title
May an Altered Hypothalamo–Pituitary–Adrenal Axis Contribute to Cortical Bone Damage in Primary Hyperparathyroidism?
Authors
Laura Gianotti
Francesco Tassone
Anna Pia
Silvia Bovio
Giuseppe Reimondo
Gianluca Visconti
Massimo Terzolo
Giorgio Borretta
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 6/2009
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-009-9245-7

Other articles of this Issue 6/2009

Calcified Tissue International 6/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.